Clinical trials
Completed Phase 2 Pulmonary Arterial Hypertension trials
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
58 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2002 | 1 |
| 2004 | 1 |
| 2005 | 1 |
| 2006 | 1 |
| 2007 | 3 |
| 2008 | 2 |
| 2009 | 4 |
| 2010 | 4 |
| 2011 | 6 |
| 2012 | 4 |
| 2013 | 2 |
| 2014 | 3 |
| 2015 | 1 |
| 2016 | 3 |
| 2017 | 2 |
| 2018 | 4 |
| 2019 | 7 |
| 2020 | 2 |
| 2021 | 1 |
| 2022 | 3 |
| 2023 | 2 |
| 2024 | 1 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Completed | 58 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Lung Biotechnology PBC | 4 |
| United Therapeutics | 4 |
| Actelion | 3 |
| GlaxoSmithKline | 3 |
| University of Pennsylvania | 3 |
| Acceleron Pharma, Inc., a wholly-owned subsidiary of Merck & Co., Inc., Rahway, NJ USA | 2 |
| Bial - Portela C S.A. | 2 |
| Geno LLC | 2 |
| Gilead Sciences | 2 |
| Respira Therapeutics, Inc. | 2 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Pulmonary Arterial Hypertension | 58 |
| Hypertension, Pulmonary | 16 |
| Familial Primary Pulmonary Hypertension | 5 |
| Idiopathic Pulmonary Fibrosis | 4 |
| Lung Diseases, Interstitial | 3 |
| Lung Diseases | 2 |
| Pulmonary Fibrosis | 2 |
| Autoimmune Diseases | 1 |
| Cardiovascular Diseases | 1 |
| Cryptogenic Organizing Pneumonia | 1 |
Trials
Showing 1 to 25 of 58. Each trial links to its page on Pharma Observatory.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.